Pediatric Exclusivity May Overcompensate Blockbuster Products – JAMA Study
Executive Summary
The net economic return to companies granted pediatric exclusivity ranged from $8.9 million to $507 million, researchers found in a study of the economic impact of the pediatric exclusivity program
You may also be interested in...
Pediatric Exclusivity 90-Day Review Can Be “Difficult” Target – Kweder
FDA sometimes is challenged to meet the deadline for completing the review of whether a drug sponsor's clinical trials in children qualify a product for pediatric exclusivity, Office of New Drugs Deputy Director Sandra Kweder indicated May 22
Pediatric Exclusivity 90-Day Review Can Be “Difficult” Target – Kweder
FDA sometimes is challenged to meet the deadline for completing the review of whether a drug sponsor's clinical trials in children qualify a product for pediatric exclusivity, Office of New Drugs Deputy Director Sandra Kweder indicated May 22
Pediatric Studies Become Costlier; Congress May Make Them Less Profitable
Drug companies are spending eight times more money to carry out a pediatric study than they were six years ago, Tufts University researchers found in a recent industry survey
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: